Spots Global Cancer Trial Database for Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Official Title: Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma
Study ID: NCT00954005
Conditions
Interventions
Study Description
Brief Summary: The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum Ludwigshafen, Ludwigshafen, , Germany
Contact Details
Name: Martin Hoffmann, Dr.
Affiliation: German Low Grade Lymphoma Study Group
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
